EWTX Edgewise Therapeutics, Inc.

Nasdaq edgewisetx.com


$ 23.06 $ 2.50 (12.21 %)    

Friday, 14-Nov-2025 14:24:56 EST
QQQ $ 611.44 $ 11.88 (1.98 %)
DIA $ 473.25 $ 1.91 (0.41 %)
SPY $ 674.28 $ 8.85 (1.33 %)
TLT $ 88.96 $ -0.83 (-0.92 %)
GLD $ 376.61 $ 3.74 (1 %)
$ 20.42
$ 20.27
$ 22.95 x 1
$ 23.03 x 77
$ 20.27 - $ 23.48
$ 10.60 - $ 35.50
1,089,003
na
2.16B
$ 1.60
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 11-06-2025 09-30-2025 10-Q
2 08-07-2025 06-30-2025 10-Q
3 05-08-2025 03-31-2025 10-Q
4 03-03-2025 12-31-2024 10-K
5 11-07-2024 09-30-2024 10-Q
6 08-08-2024 06-30-2024 10-Q
7 05-09-2024 03-31-2024 10-Q
8 02-22-2024 12-31-2023 10-K
9 11-09-2023 09-30-2023 10-Q
10 08-10-2023 06-30-2023 10-Q
11 05-11-2023 03-31-2023 10-Q
12 02-23-2023 12-31-2022 10-K
13 11-03-2022 09-30-2022 10-Q
14 08-04-2022 06-30-2022 10-Q
15 05-11-2022 03-31-2022 10-Q
16 02-24-2022 12-31-2021 10-K
17 11-10-2021 09-30-2021 10-Q
18 08-09-2021 06-30-2021 10-Q
19 05-13-2021 03-31-2021 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 jp-morgan-maintains-overweight-on-edgewise-therapeutics-raises-price-target-to-34

JP Morgan analyst Tessa Romero maintains Edgewise Therapeutics (NASDAQ:EWTX) with a Overweight and raises the price target f...

 rbc-capital-maintains-outperform-on-edgewise-therapeutics-raises-price-target-to-50

RBC Capital analyst Leonid Timashev maintains Edgewise Therapeutics (NASDAQ:EWTX) with a Outperform and raises the price tar...

 wedbush-maintains-outperform-on-edgewise-therapeutics-lowers-price-target-to-32

Wedbush analyst Laura Chico maintains Edgewise Therapeutics (NASDAQ:EWTX) with a Outperform and lowers the price target from...

 edgewise-therapeutics-q3-eps-039-beats-040-estimate

Edgewise Therapeutics (NASDAQ:EWTX) reported quarterly losses of $(0.39) per share which beat the analyst consensus estimate of...

 jp-morgan-maintains-overweight-on-edgewise-therapeutics-lowers-price-target-to-30

JP Morgan analyst Tessa Romero maintains Edgewise Therapeutics (NASDAQ:EWTX) with a Overweight and lowers the price target f...

 rbc-capital-maintains-outperform-on-edgewise-therapeutics-raises-price-target-to-49

RBC Capital analyst Leonid Timashev maintains Edgewise Therapeutics (NASDAQ:EWTX) with a Outperform and raises the price tar...

 edgewise-therapeutics-q2-eps-034-beats-043-estimate

Edgewise Therapeutics (NASDAQ:EWTX) reported quarterly losses of $(0.34) per share which beat the analyst consensus estimate of...

 hc-wainwright--co-initiates-coverage-on-edgewise-therapeutics-with-buy-rating-announces-price-target-of-42

HC Wainwright & Co. analyst Joseph Pantginis initiates coverage on Edgewise Therapeutics (NASDAQ:EWTX) with a Buy rating...

 no-accelerated-fda-approval-for-edgewises-rare-muscular-disease-drug-shares-fall

Edgewise reports sustained functional stability in Becker patients and selects Phase 3 dose for Duchenne after positive Phase 2...

 edgewise-therapeutics-reports-results-in-sevasemten-program-for-becker-and-duchenne-muscular-dystrophies

Edgewise Therapeutics, Inc., (NASDAQ:EWTX), a leading muscle disease biopharmaceutical company, today unveiled positive results...

 rbc-capital-reiterates-outperform-on-edgewise-therapeutics-maintains-48-price-target

RBC Capital analyst Leonid Timashev reiterates Edgewise Therapeutics (NASDAQ:EWTX) with a Outperform and maintains $48 price...

 edgewise-therapeutics-q1-eps-043-inline

Edgewise Therapeutics (NASDAQ:EWTX) reported quarterly losses of $(0.43) per share which met the analyst consensus estimate. Th...

 wedbush-maintains-outperform-on-edgewise-therapeutics-maintains-43-price-target

Wedbush analyst Laura Chico maintains Edgewise Therapeutics (NASDAQ:EWTX) with a Outperform and maintains $43 price target.

 rbc-capital-maintains-outperform-on-edgewise-therapeutics-lowers-price-target-to-52

RBC Capital analyst Leonid Timashev maintains Edgewise Therapeutics (NASDAQ:EWTX) with a Outperform and lowers the price tar...

 scotiabank-downgrades-edgewise-therapeutics-to-sector-perform-lowers-price-target-to-14

Scotiabank analyst Louise Chen downgrades Edgewise Therapeutics (NASDAQ:EWTX) from Sector Outperform to Sector Perform and l...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION